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ABSTRACT
Background: Although lung transplantation is a well-accepted treatment for end-stage lung diseases pa-tients, only 15%–20% of the brain-dead donors’ lungs are usable for transplantation. This results in high mortality of candidates on waiting lists. Ex-vivo lung perfusion (EVLP) is a novel method for better evalu-ation of a potential lung for transplantation.
Objective: To report the first experience of EVLP in Iran.
Methods: The study included a pig in Vienna Medical University, Vienna, Austria, and 4 humans in Masih 
Daneshvari Hospital, Tehran, Iran. All brain-dead donors from 2013 to 2015 in Tehran were evaluated for 
EVLP. Donors without signs of severe chest trauma or pneumonia, with poor oxygenation were included.
Results: An increasing trend in difference between the pulmonary arterial pO2 and left atrial pO2, an in-creasing pattern in dynamic lung compliance, and a decreasing trend in the pulmonary vascular resis-tance, were observed. 
Conclusion: The initial experience of EVLP in Iran was successful in terms of important/critical param-eters. The results emphasize on some important considerations such as precisely following standard lung harvesting and monitoring temperature and pressure. EVLP technique may not be a cost-effective option 
for low-income countries at first glance. However, because this is the only therapeutic treatment for end-
stage lung disease, it is advisable to continue working on this method to find alternatives with lesser costs.
KEYWORDS: Lung transplantation; Ex-vivo lung perfusion; Brain-dead donor; Lung transplantation technique
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INTRODUCTION
The first successful lung transplantation 
(LTx) was done in 1983 by the Toronto Lung 
Transplant group [1]. Approximately 4000 
transplantations are performed annually 
worldwide, according to the International So-
ciety for Heart and Lung Transplantation reg-
istries [2].
Nowadays, lung transplantation is accepted as 
a well-established treatment for patients with 
end-stage lung disease. Although the num-
ber of lung transplant candidates has grown 
significantly, only 15%–20% of brain-dead 
donors’ lungs are usable for transplantation. 
This results in a high mortality among lung 
transplant candidates on waiting lists. Some 
European centers reported that up to 50% of 
lung transplant candidates die while on wait-
ing lists [3, 4].
Greater susceptibility of the lungs to deleteri-
ous effects of brain death (i.e., inflammatory 
response) and ICU complications (prolonged 
intubation, pneumonia, barotrauma and ex-
cessive crystalloid injection) results in low 
rate of available lungs as a transplant [5, 6]. 
However, in recent years, various strategies 
have been proposed to increase the number of 
transplanted lungs using marginal lung and 
non-heart-beating donor. There is however, 
evidence suggesting an increased incidence 
of some complications, such as primary graft 
dysfunction, in recipients of such marginal or-
gans [7, 8]. 
To overcome two main limitations—scarcity 
of donor lungs and post-operative complica-
tions—a novel approach, namely ex vivo lung 
perfusion (EVLP), has been established by 
Steen, et al [9]. In this operation, poorly oxy-
genated lungs (paO2 < 300 mm Hg with FIO2 
100%) with pulmonary edema or atelectasis 
without established pneumonia, severe contu-
sions or gross gastric aspiration are perfused 
ex vivo by a high oncotic pressure solution, the 
so-called “Steen solution,” and then ventilated 
for time points, and monitored on time. In 
condition with difference between the pulmo-
nary arterial pO2 and the left atrial pO2 (de-
fined as ΔpO2) is more than 350 mm Hg and 
other functional parameters (dynamic lung 
compliance, peak inspiratory pressure, pulmo-
nary artery pressure, and pulmonary vascular 
resistance) are stable or improved after a mini-
mum of 2 hours of EVLP, the lungs are con-
sidered as a candidate for transplantation [7]. 
For the first time using this method in 2005, a 
successful EVLP was performed on a 19-year-
old brain-dead donor that was rejected for 
LTx by all lung transplant centers in the Lund 
University Hospital, Sweden. The recipient 
was a 70-year-old man with chronic obstetric 
pulmonary disease, who became socially very 
active after LTx. Unfortunately, he died of 
acute sepsis 11 months after the transplanta-
tion [9]. There have been several prospective 
completed and ongoing clinical trials of vari-
ous EVLP techniques in Europe and North 
America. It can be addressed to HELP trial 
in Toronto, NOVEL and Perfusix trials in the 
USA, Vienna trial in Austria using Toronto 
method, INSPIRE and EXPAND trials in the 
USA and Europe with OCS method, and DE-
VELOP trial in the UK using Steen method 
[10]. 
Herein, we present our experience with this 
technique in Iran.
Table 1: Strategy for initiation of ex vivo lung perfusion
Perfusion time (min) 0 10 20 30 40 50 60
Termination temp (°C) 20 30 32-35 37 37 37 37
Flow (% Calculated flow) 10 10 20 30 50 80 100
Ventilation None None Start Recruitment
Gas exchanger None None Start
Left arterial pressure (mm Hg) 3–5 3–5 3–5 3–5 3–5 3–5 3–5
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MATERIALS AND METHODS
Study Design
This study included five cases: a pig in Vienna 
Medical University, Vienna, Austria, and four 
humans in Masih Daneshvari Hospital, Teh-
ran, Iran. All brain-dead multi-organ donors 
from May 2013 to July 2015 in Tehran were 
evaluated for the inclusion criteria of lung 
transplantation or EVLP. The pig case was 
arranged to make the Iranian team qualified 
for EVLP. Theoretical and practical points 
including lung harvesting, antegrade and ret-
rograde lung flushing, left-atrium (LA) and 
pulmonary artery (PA) anastomosis, cannula-
tion, perfusion, ventilation, and periodic lung 
assessment were all discussed.
Inclusion and Exclusion Criteria
Donors younger than 65 years with his-
tory of smoking <20 pack/day, ratio of arte-
rial pO2 (paO2) to fraction of inspired oxygen 
(FIO2) <300 mm Hg, without any significant 
improvement by recruitment maneuver and 
chest radiographic findings suggestive of pul-
monary edema, defined as bilateral interstitial 
infiltration, were included in this study. Ex-
clusion criteria included donor lungs with es-
tablished pneumonia, severe mechanical lung 
injury (i.e., contusions in more than one lobe) 
or gross gastric aspiration.
Ex Vivo Lung Perfusion Technique
Toronto technique, used in this study, was 
developed by Cypel, et al, which allows pro-
longed perfusion, organ recovery and active 
treatment for organ repair along with lung 
assessment. More details of acellular EVLP 
technique are provided elsewhere [11]. 
Briefly, the circuit was primed with 2 liters 
of Steen solution (XVIVO, Vitrolife, Sweden). 
In addition, 500 mg of imipenem/cilastatin 
(Jaberebne Hayan Pharmaceutical Company, 
Tehran, Iran), 3000 IU of heparin (Caspian 
Tamin Pharmaceutical Company, Rasht, Iran), 
and 500 mg of methylprednisolone (Solu-Me-
drol, Sandoz Canada, Boucherville, Canada) 
were added to the perfusate solution. Table 1 
demonstrates the Toronto initiation strategy.
After the first hour of EVLP, 500 mL of circu-
lated perfusate was removed and replenished 
with 500 mL of fresh solution. Subsequently, 
250 mL was exchanged every hour until the 
end of the procedure. After transferring lungs 
to the XVIVO chamber, the pulmonary artery 
and LA cannulas (XVIVO) were connected to 
the circuit and anterograde flow was started 
at 150 mL/min of the perfusate at room tem-
perature. The temperature of the perfusate 
was then gradually increased to 37 °C. When 
the temperature of 32 °C was reached (usu-
ally >30 min), ventilation was started and the 
perfusate flow rate was increased gradually. 
A flow of mixed gas of N2, O2, and CO2 (Ro-
ham Gas, Iran) was used to deoxygenate and 
provide carbon dioxide to the inflow perfus-
ate via a gas exchange membrane which was 
initiated at 1 L/min and adjusted according to 
the arterial blood gas analysis. In this method, 
mechanical ventilation is based on protective 
mode with perfusion flow limited to 40% of 
the cardiac output, pulmonary arterial pres-
sure of 7–15 mm Hg, and a LA pressure of 5 
mm Hg in a closed circuit. 
At the final step, the lung block was cooled 
down in the circuit to 10 °C within a 10-min 
period. Thereafter, perfusion and ventila-
tion were stopped (FIO2 increased to 50% for 
lung storage), and the trachea was clamped to 
maintain the lungs in an inflated state. The 
lungs were then statically preserved at 4 °C 
in Perfadex until transplantation. The main-
Table 2: EVLP maintanace strategy settings
Measure Setting
Tidal volume 6–8 mL/kg
PEEP 5 cm H2O
Respiratory rate 7 breaths/min
FIO2 21%
Flow rate 40% of estimated cardiac output
LAP 3–5 mm Hg
PAP 10–15 mm Hg
Recruitments To PawP of 25 cm H2O 
PEEP: positive end-expiratory pressure; FIO2: fraction inspired 
of oxygen; LAP: left atrial pressure; PAP: mean pulmonary artery 
pressure; Recruitments were performed by 2 inspiratory holds of 
15 seconds to a PawP (peak airway pressure) of 25 cm H2O every 
hour.
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tenance strategy is presented in Table 2. Fig-
ures 1 and 2 show the circuit diagram and a 
lung on EVLP system, respectively.
Ex Vivo Functional Assessment
This method was done as described earlier 
[11]. The pH, pCO2, electrolytes, and glucose 
were maintained at physiological levels in the 
perfusate. For the functional assessment of ex 
vivo, the tidal volume was set at 10 mL/kg of 
donor body weight and 10 breaths/min for 5 
min with an FIO2 of 1.0. Lung function was 
evaluated hourly during EVLP according to 
the following equations:
ΔpO2 = LA pO2 – PA pO2 (mm Hg),
and 
Figure 1: Ex vivo lung perfusion circuit. Circuit 1: Steen solution from bottle to reservoir of cardio-pulmonary 
bypass pump; Circuit 2: Steen circulated from reservoir to centrifugal pump; Circuit 3: circulation from centrifu-
gal pump to membrane; Circuit 3': circulation of mixed gas from gas cylinder to membrane, circuit a: solution 
from membrane to heater-cooler, circuit b: solution from heater-cooler to membrane; Circuit 4: solution from 
membrane to leukocyte filter; Circuit 5: solution from leukocyte filter to pulmonary artery; Circuit 6: returning 
solution from left atrium to reservoir, circuit c: returning solution residue from chamber to reservoir through 
roller suction, purple circuit: solution and lung temperature monitoring. 
Figure 2: Lung on the EVLP system
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(PA pressure - LA pressure) 80Pulmonary Vascular Resistance = 
Pulmonary Artery Flow
´
(in dynes·sec·cm-5), dynamic compliance (in 
mL/cm H2O), and peak inspiratory pressure 
(in cm H2O). Radiography of the ex vivo lung 
and flexible bronchoscopy were performed at 
1 and 3 hours of EVLP.
RESULTS
A total of five cases including one pig and four 
humans were studied. An increasing trend in 
ΔpO2 was observed in all of the cases. In ad-
dition, there was an increasing trend in other 
functional parameters including dynamic lung 
compliance, and also a decreasing trend in 
the pulmonary vascular resistance. Although 
the observed improved trends were accept-
able, they did not meet the end-point we had 
defined—a ΔpO2 = 350 mm Hg. In the pig, 
ΔpO2 increased up to 330 mm Hg; the lung 
compliance and pulmonary vascular resis-
tance were acceptable. 
A 47-year-old brain-dead donor due to cere-
brovascular accident was selected as the sec-
ond case. All cannulations were connected to 
the circuit and normal saline was injected to 
the circulation instead of Steen. Soon, problems 
related to the anastomosis, cannulations, air 
leak, and liquid leak were observed. The third 
case was a 63-year-old  non-smoker brain-
dead due to a benign brain tumor who had 
been intubated for 9 days with a paO2/ FIO2 of 
125 mm Hg, pulmonary edema in both lungs 
and normal bronchoscopy findings. EVLP 
was started after 130 min of aortic clamp; the 
anastomosis was satisfying, but there were 
problems with air leak in the circuit and liquid 
leak from the site of lung biopsy that had been 
done for research purposes. At the end, foamy 
yellowish secretions, which were suggestive 
of pulmonary edema, were removed from the 
lungs. ΔpO2 increased from 19 to 110 mm Hg. 
PVR at first decreased from 780 to 360 but 
increased to 800 dynes·sec·cm-5. Improved re-
sults were seen in the fourth case, a 43-year-
old brain-dead donor due to hypertension 
crisis, with a paO2/ FIO2 of 220 mm Hg that 
increased to 260 after recruitment maneuver, 
obvious atelectasis in right lung, and nor-
mal bronchoscopy findings. His lungs were 
been harvested in another center, kept in ice 
coalman for one hour, and finally underwent 
EVLP in Masih Daneshvari Hospital. Time 
between aortic clamp and starting EVLP was 
180 min. Pressures were kept at an overall ac-
ceptable level in this case, however there were 
problems with temperature monitoring, espe-
cially during the first 30 min. ΔpO2 increased 
from 62 to 223 mm Hg, in addition, PVR de-
creased from 350 to 130 at the beginning and 
then increased to 444 dynes·sec·cm-5. Lung 
dynamic compliance improved from 44 to 69 
mL/cm H2O and stabilized around 45. 
In the fifth case, all principles of harvesting 
were accurately applied; prostacycline was 
carefully injected; sufficient amount of time 
was spared to let the lungs cool down during 
harvesting and before the onset of ELVP, how-
ever, a LA pressure of 3–5 mm Hg was not 
met and due to some technical problems a sud-
den shift of fluid into the lungs was occurred 
and so the process had to be terminated. For-
tunately, the system was successfully set up, 
and promising results were growing by the 
hour. ΔpO2 in liquid samples was increasing 
so that it reached 230 mm Hg in the fifth hour, 
while it was 65 mm Hg at the onset. The de-
tails of perfusion evaluation of the third and 
fourth cases are shown in Tables 3 and 4, re-
spectively.
DISCUSSION
Shortage of suitable lung and post-operative 
complications such as primary graft dysfunc-
tion motivated our team to establish a study 
for approaching the ex vivo normothermic 
perfusion. 
We have reported herein strategy for EVLP 
of the donor lung. Some technical hints have 
been considered as key elements to reach a suc-
cessful EVLP. EVLP is not a single technique; 
it is a collection of many arts and methods 
that should be carefully followed to improve a 
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marginal donor lung. In the current study, the 
animal model provided information to start 
the human model. In the animal model, we 
reached a successful trend in ΔpO2 status and 
the functional parameters. 
Some successful lung transplantation teams 
have had an EVLP success rate of about 60% 
[7]. Therefore, it can be concluded that our 
initial experience indicated a considerable im-
provement in the initial establishment of this 
technique in Iran. To conduct an EVLP sys-
tem in a center, it is mandatory for the team 
members to be highly qualified. Particularly, 
for low experienced centers, it is advisable to 
consider selection of donor and avoid choosing 
extreme marginal lungs in the initial steps. 
The team should follow the standard lung 
harvesting such as a conventional lung trans-
plantation including core and surface cooling 
and administration of prostaglandin during 
the harvest. Another important point is to pay 
attention to storing the lung at 4 °C between 
harvest and EVLP to decrease cellular metab-
olism at the basal level, and also not to start 
EVLP immediately after lung removal. It is 
necessary to monitor the lung and the solution 
temperature and pressure precisely. A compre-
hensive discussion about the whole process of 
EVLP in terms of the four phases are available 
elsewhere [12].
Based on the initial results, EVLP can lead 
to a great change and a remarkable progres-
sion in lung transplantation in Iran, given the 
well-experienced team. It is suggested that 
this operation to be continued seriously to 
achieve more significant successful results in 
the near future. As lung transplant is not cur-
rently under coverage of insurance companies 
in Iran, the average cost of a conventional lung 
transplantation and an EVLP is estimated at 
US$ 22,800 and US$ 15,000, respectively. 
Saving human’s life is the reason why such 
services should be supported. Lung transplan-
tation, like heart and liver transplantation, is 
a life-saving process. In 2014, only 14 lung 
transplantations were done in Iran. About 480 
patients with end-stage lung disease are re-
ferred to lung transplant clinics annually, of 
whom 160 can be listed as active candidates. 
The first and the most important obstacle en-
countered in this way is the shortage of suit-
able organs. Although 260 brain-dead patients 
were reported last year in Tehran, only 5%–
10% of them had suitable lungs for transplan-
tation. Lungs were rejected mostly because of 
insufficient ICU care, and also during trauma 
as the most common cause of brain death in 
Iran; the rate of aspiration pneumonia is also 
high.
One of the limitations of our study was the low 
sample size of this study that was attributed to 
the financial issues. It is highly recommend-
ed to conduct future studies on more cases in 
order to gain a better understanding as well 
as reconditioning brain-dead lungs safely for 
lung transplantation and immunological in-
vestigations.
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